



LAB ALERT

Ryan H. Livengood, M.D., Laboratory Medical Director

RL

Pathology and Laboratory Medicine

Test Change: NT-proBNP to replace BNP on 7/16/2025

Facility: BMC & JMC

The current B-type natriuretic peptide (BNP) testing equipment at BMC and JMC Laboratories will be decommissioned and testing moved to Abbott Alinity analyzers on 7/16/2025. This change transitions to a **new** NT-proBNP assay and aligns with system standardization efforts.

BNP is synthesized and secreted into the blood by cardiac myocytes in response to volume overload, increased ventricular wall stress, and ventricular hypertrophy and can be a useful test in heart failure when interpreted in conjunction with patient history, physical examination, and imaging procedures.

A variety of FDA-approved assays have been developed based on the precursor proBNP or one of the cleaved products BNP or NT-proBNP. Though similar in utility, the new and outgoing tests are slightly different analytically. Results of the new NT-proBNP test will be reported on a different line in results review and will not graph together with results of the outgoing test.

Impaired renal function is associated with increased NTproBNP (decreased clearance). Also, age significantly affects NT-proBNP levels, so age-dependent comments will be provided in Epic:

Negative: Heart failure unlikely.	
All ages	<300 pg/mL
Grayzone: Indeterminate. Consider other causes of NT-proBNP elevation	
18-49 yrs	≥300.0 - <450.0 pg/mL
50-75 yrs	≥300.0 - <900.0 pg/mL
>75 yrs	≥300.0 - <1800.0 pg/mL
Positive: Heart failure likely.	
18-49 yrs	≥450.0 pg/mL
50-75 yrs	≥900.0 pg/mL
>75 yrs	≥1800 pg/mL

*For questions call BMC Lab at 304-264-1212, option #7, or JMC Lab at 304-728-1759

Effective Date: July 16, 2025